NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novelion Therapeutics's change in receivables for the quarter that ended in Mar. 2019 was $1.9 Mil. It means Novelion Therapeutics's Accounts Receivable declined by $1.9 Mil from Dec. 2018 to Mar. 2019 .
Novelion Therapeutics's change in receivables for the fiscal year that ended in Dec. 2018 was $-6.7 Mil. It means Novelion Therapeutics's Accounts Receivable increased by $6.7 Mil from Dec. 2017 to Dec. 2018 .
Novelion Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2019 was $26.9 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Novelion Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2019 was 76.16.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novelion Therapeutics's liquidation value for the three months ended in Mar. 2019 was $-382.3 Mil.
The historical data trend for Novelion Therapeutics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 0.07 | 0.01 | -0.89 | -12.85 | -6.75 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Change In Receivables | Get a 7-Day Free Trial | 6.13 | -2.34 | -3.23 | -7.31 | 1.92 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics (OTCPK:NVLNF) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Novelion Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2019 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 26.875 | / | 32.2 | * | 91 |
= | 76.16 |
2. In Ben Graham's calculation of liquidation value, Novelion Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Novelion Therapeutics's liquidation value for the quarter that ended in Mar. 2019 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 51.919 | - | 461.069 | + | 0.75 * 26.875 | + | 0.5 * 13.407 |
= | -382.3 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Novelion Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 10-04-2019
By Marketwired Marketwired • 02-06-2019
By GlobeNewswire GlobeNewswire • 03-31-2019
By Marketwired Marketwired • 07-17-2019
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 08-13-2019
By Marketwired Marketwired • 03-31-2019
By PRNewswire PRNewswire • 11-12-2018
By Marketwired Marketwired • 08-22-2019
By GlobeNewswire GlobeNewswire • 09-11-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.